Abstract. The granzyme B-induced cell death has been traditionally viewed as a primary mechanism that is used by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells to eliminate harmful target cells including allogeneic, virally infected and tumour cells. Granzyme B (GrB) is the most abundant serine protease which is stored in secretory granules of CTLs and NK cells. After recognition of the target cell, the engaged CTLs and NK cells vectorially secrete GrB along with other granule proteins including perforin into the immunological synapse. From this submicroscopic intercellular cleft GrB translocates into the cytoplasm of the target cell. Although several models have been proposed to explain the GrB delivery mechanism, conclusive understanding of this process remains still elusive. Once in the cytoplasm, GrB cleaves and activates, or inactivates, multiple protein substrates, resulting eventually into apoptotic demise of the target cell. This review is focused on the gene structure and expression of GrB, its biosynthesis and activation, delivery mechanisms into the target cell cytoplasm, direct proteolytic involvement in activation of several pro-apoptotic pathways, and on regulation of its activity in cancer cells. Moreover, emphasis is given to the GrB-mediated anticancer effects and future clinical applications of the GrB-based and tumour-targeted recombinant fusion constructs.
Contents1. Introduction 2. Granzyme B gene organization and regulation of expression 3. Granzyme B biosynthesis, subcellular localization and activation 4. Granzyme B structure and substrate specificity 5. Granzyme B delivery mechanism into the target cell cytoplasm 6. Death pathways activated by granzyme B in cancer cells 7. Regulation of granzyme B activity 8. Granzyme B and anticancer therapy 9. Conclusion and the future directions of research
IntroductionSusceptibility of tumour cells to apoptotic death depends on their capabilities to express the components of apoptosis pathways and to activate them in response to extrinsic or intrinsic death signals. The extrinsic death pathways are represented by the death receptor-and the cytotoxic granulemediated pathways. On the other hand, the intrinsic death mechanisms are represented by the mitochondrial, lysosomal and PIDDosome death pathways.The death receptor pathway is triggered by the binding of a death ligand, such as FasL (also known as CD95L) and TRAIL (also known as APO-2L) to a specific transmembrane death receptors, Fas (also known as APO-1/CD95) and death receptor 4 and/or 5 (DR4, DR5), respectively (1,2). After binding of the cytosolic Fas-associated death domain adaptor protein (FADD, also known as MORT1) to the liganded death receptors, the initiator procaspase-8 and/or -10 are bound to engaged FADD completing the formation of the deathinducing signalling complexes (DISCs) (1-4). Within DISCs, procaspase-8 and -10 are activated via homodimerization and the active caspase-8 and -10, arising through interdimer proteolytic processing, dissociate from DISCs into the cyt...